Choose a language and wait for the translated text.
Shots:
Eli Lilly has entered into a definitive agreement to acquire Calytrix Bio; Calytrix shareholders could receive up to $1.5B in cash, incl. an upfront payment & subsequent clinical & regulatory milestones
The acquisition adds Calytrix’s lead preclinical biparatopic antibody, which targets both Type 1 & Type 2 mutant calreticulin (mCALR) for mCALR-driven essential thrombocythemia (ET) & myelofibrosis (MF) and is designed to deliver disease-modifying pan-mutant activity
Calytrix is a privately held biotech based in Wellesley Hills, Massachusetts, developing precision therapies for myeloproliferative neoplasms; founded in 2025 by J.P. Morgan Life Sciences Private Capital, it launched with a Series A co-led by J.P. Morgan Life Sciences Private Capital & Westlake BioPartners, followed by a Series B led by Avoro Ventures
Ref: PR Newswire | Image: Eli Lilly | Calytrix Bio | Press Release
PharmaShots, your go-to media platform for customized news ranging across multiple indications. For more information, connect with us at connect@pharmashots.com
The post Eli Lilly to Acquire Calytrix Bio for Up to $1.5B to Expand its Blood Cancer Pipeline appeared first on PharmaShots.